News coverage about China Biologic Products (NASDAQ:CBPO) has trended somewhat positive on Thursday, Accern reports. The research firm rates the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. China Biologic Products earned a daily sentiment score of 0.01 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 45.2306121051728 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the media stories that may have effected Accern Sentiment’s scoring:
- China Biologic Products (CBPO) Receives CFDA Clinical Trial Approval for Human Fibrin Sealant (streetinsider.com)
- China Biologic Gets CFDA Clinical Trial Approval For Human Fibrin Sealant (markets.businessinsider.com)
- China Biologic Receives CFDA Clinical Trial Approval for Human Fibrin Sealant (finance.yahoo.com)
- China Biologic Products Holdings Inc (CBPO) Receives Consensus Rating of “Hold” from Analysts (americanbankingnews.com)
A number of analysts have recently weighed in on the company. BidaskClub upgraded China Biologic Products from a “sell” rating to a “hold” rating in a research report on Saturday, April 7th. Deutsche Bank set a $105.00 price target on China Biologic Products and gave the stock a “buy” rating in a research report on Friday, March 2nd. Jefferies Financial Group reiterated a “buy” rating and set a $97.00 price target on shares of China Biologic Products in a research report on Thursday, March 15th. ValuEngine cut China Biologic Products from a “sell” rating to a “strong sell” rating in a research report on Wednesday, May 16th. Finally, Zacks Investment Research cut China Biologic Products from a “hold” rating to a “sell” rating in a research report on Monday, March 5th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $101.00.
CBPO traded up $0.56 during trading hours on Thursday, hitting $82.75. The company’s stock had a trading volume of 375,500 shares, compared to its average volume of 251,128. China Biologic Products has a fifty-two week low of $71.85 and a fifty-two week high of $114.82. The stock has a market cap of $2.74 billion, a P/E ratio of 16.71, a P/E/G ratio of 1.35 and a beta of 1.47.
China Biologic Products (NASDAQ:CBPO) last posted its earnings results on Friday, May 4th. The biopharmaceutical company reported $1.21 EPS for the quarter, missing the consensus estimate of $1.22 by ($0.01). China Biologic Products had a net margin of 17.76% and a return on equity of 17.29%. The business had revenue of $112.50 million during the quarter, compared to analyst estimates of $118.25 million. During the same quarter in the prior year, the business earned $1.32 earnings per share. The firm’s revenue was up 23.0% compared to the same quarter last year. equities analysts predict that China Biologic Products will post 4.71 EPS for the current fiscal year.
About China Biologic Products
China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.
Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.